Role of progesterone and other neuroactive steroids in anxiety disorders

Expert Review of Neurotherapeutics

Volumn 4, Issue 5, 2004, Pages 851-860

  Le Mellédo, Jean Michel ^a,b   Baker, Glen Bryan ^b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anxiety; Neuroactive steroids; Neurosteroids; Panic; Progesterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANXIOLYTIC AGENT; NEUROSTEROID; PROGESTERONE; PROGESTERONE DERIVATIVE;

ANXIETY DISORDER; HORMONAL REGULATION; HUMAN; NEUROCHEMISTRY; NEUROMODULATION; NEUROPSYCHIATRY; PROGESTERONE METABOLISM; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ANIMALS; ANXIETY DISORDERS; BRAIN; DEHYDROEPIANDROSTERONE; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; PROGESTERONE; RECEPTORS, GABA-A; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; TIME FACTORS;

EID: 4444325500     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.5.851     Document Type: Review

References (114)

1. Kessler RC, McGonagle KA, Nelson CB et al. Lifetime and 12 months prevalence of DSM-III-R psychiatric disorders in the United States; results from the National Comorbidity Survey. Arch Gen. Psychiatry 51, 8-19 (1994).
2. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am. J. Psychiatry 157, 669-682 (2000).
3. Greenberg PE, Sisitsky T, Kessler RC et al. The economic burden of anxiety disorders in the 1990s. J. Clin. Psychiatry 60, 427-435 (1999).
4. Dick CL, Bland RC, Newman SC. Panic disorder. Acta Psychiatrica Scandinavia 376, 45-53 (1994).
5. Weissman MM, Bland RC, Canino GJ et al. The cross-national epidemiology of panic disorder. Arch Gen. Psychiatry 54, 305-309 (1997).
6. Gater R, Tansella, M, Korten A et al. Sex differences in the prevalence and detection of depressive and anxiety disorders in general healthcare settings. Arch. Gen. Psychiatry 55, 405-413 (1998).
7. Faravelli C, Zucchi T, Viviani B et al. Epidemiology of social phobia: a clinical approach. Eur. Psychiatry 15, 17-24 (2000).
8. Yonkers KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual dysphoric disorders. J. Gin. Psychiatry 58(Suppl), 62-69 (1997).
9. Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. Impact of pregnancy on panic disorder a case series. J. Clin. Psychiatry 55, 284-288 (1994).
10. Cohen LS, Sichel DA, Faraone SV et al. Course of panic disorder during pregnancy and the puerperium: a preliminary study. Biol. Psychiatry 39, 950-954 (1996).
11. Northcott CJ, Stein MB. Panic disorder in pregnancy. J. Clin. Psychiatry 55, 539-542 (1994).
12. May W, Vallée M, Darnaudéry M, Le Moal M. Potentiation of GABAergjc neurotransmission by steroids. In: Contemporary Endocrinology: Neurosteroids: a New Regulatory Function in the Nervous System. Baulieu EE, Robel P, Schumacher M (Eds). Humana Press, Totowa, NJ, USA, 317-335 (1999).
13. Purdy RH, Paul SM. Potentiation of GABAergic neurotransmission by steroids. In: Contemporary Endocrinology: Neurosteroids: a New Regulatory Function in the Nervous System. Baulieu EE, Robel P, Schumacher M. (Eds). Humana Press, Totowa, NJ, USA, 143-153 (1999).
14. Mayo W, Vallee M, Darnaudry M, Le Moal M. Neurosteroids. Behavioral studies. In: Contemporary Endocrinology: Neurosteroids: a New Regulatory Function in the Nervous System. Baulieu EE, Robe LP, Schumacher M (Eds). Humana Press, Totowa, NJ, USA, 317-335 (1999).
15. Bixo M, Anderson A, Windblad B, Purdy RH, Backstrome T. Progesterone, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 764(1-2), 173-178 (1997).
16. Chouinard G, Annable L, Fontain R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology 77, 229-233 (1982).
17. Ballenger JC, Burrows GD, DuPont RL et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: I effcicacy in short-term treatment. Arch Gen. Psychiatry 45, 413-422 (1988).
18. Davidson JR, Potts N, Ritchie E et al. Treatment of social phobia with clonazepam and placebo. J. Clin. Psychopharmacology 13, 423-428 (1993).
19. Feltner DE, Robinson P, Janney C, Panse A. A placebo-controlled study of pregabalin treatment of social phobia. American College of Neuropsychopharmacology meeting, Hawaii, USA (1998).
20. Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. 19, 341-348 (1999a).
21. Pande AC, Crockatt JG, Janney CA, Feltner DE. Pregabalin, a novel agent, in the treatment of generalized anxiety disorder. American College of Neuropsychopharmacology Meeting, Acapulco, Mexico (1999b).
22. Nutt DJ, Glue P, Lawson CW, Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine sensitivity in panic disorder. Arch. Gen. Psychiatry 47, 917-925 (1990).
23. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch. Gen. Psychiatry 47, 534-538 (1990).
24. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder. Preliminary results from a quantitative PET study. Arch. Gen. Psychiatry 55, 715-720 (1998).
25. Bremner JD, Innis RB, White T et al. Spect (I-123) Iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol. Psychiatry 47, 96-106 (2000).
26. Weizman R, Tanne Z, Granek M et al. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur. J. Pharmacol. 138, 289-292 (1987).
27. Ferrarese C, Appollonio I, Frigo M et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr. Scand. 82, 169-173 (1990).
28. Rocca P, Ferrero P, Gualerzi A et al. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr. Scand. 84, 537-544 (1991).
29. Cowley DS, Roy-Byrne PP, Hommer D et al. Benzodiazepine sensitivity in anxiety disorders. Biol. Psychiatry 29, 57 (1991).
30. Tiihonen J, Kuikka J, Räsänen P et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol. Psychiatry 2, 463-471 (1997).
31. Malizia AL, Coupland NJ, Nutt DJ. Benzodiazepine receptor function in anxiety disorders. In: GABA Receptors and Anxiety: From Neurobiology to Treatment. Biggio G, Sanna E, Costa E (Eds). Raven Press, NY, USA, 115-133 (1995).
32. A receptor function. Pharmacol. Biochem. Behav. 45, 423-428 (1993).
33. A receptor.
34. Picazo O, Fernandez-Guasti A. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. Brain Res. 680, 135-141 (1995).
35. Bradwejn J, Koszycki D, Schriqui C. Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder. Arch. Gen. Psychiatry 48, 603-607 (1991).
36. Abelson JL, Nesse M. Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses. Biol. Psychiatry 36, 73-83 (1994).
37. Le Mellédo J-M, Ghandri JS, Lott P et al. The effect of medroxyprogesterone pretreatment on the response to pentagastrin in female panic disorder patients. Psychiatry Res. 2001, 237-242 (2001).
38. A receptor and consequently the receptor's pharmacology
39. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbituate-like modulators of the GABA receptor. Science 232, 1004-1007 (1986).
40. Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38, 379-395 (1992).
41. Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 6, 2311-2322 (1992).
42. A receptor. Brain Res. 561, 157-161 (1991).
43. Wieland S, Belluzzi JD, Stein L, Lan NC. Comparative behavioural characterization of the neuroactive steroids 3αOH,5β-pregnan-20-one and 3αOH,5β-pregnan-20-one in rodents. Psychopharmacology 118, 65-71 (1995).
44. Patchev VK, Shoib M, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62, 265-271 (1994).
45. A receptor.
46. Akwa Y, Purdy RH, Koob GF, Britton KT. The amygdala mediates the anxiolytic effect of the neurosteoid allopregnanolone in rat. Behav. Brain Res. 106, 119-125 (1999).
47. Bitran D, Dugan M, Renda P, Ellis R, Foley M. Anxiolytic effects of the neuroactive steroid pregnanolone (3α-OH,5β-pregnan-20-one) after microinjection in the dorsal hippocampus and the lateral septum. Brain Res. 850, 217-224 (1999).
48. Fernandez-Guasti A, Picazo O. Sexual differentiation modifies the allopragnanolone anxiolytic actions in rats. Psychoneuroendocrinology 24, 251-267 (1999).
49. Bitran D, Foley M, Audette D, Leslie N, Frye CA. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rats. Psychopharmacology 151, 64-71 (2000).
50. Bitran D, Klibansky ZDA, Martin GA. The neurosteroid pregnanolone sulfate prevents the anxiogenic-like effect of inescable shock in the rat. Psychopharmacology 151, 31-37 (2000).
51. Barbaccia ML, Roscetti G, Trabucchi M et al. Isoniazid-induced inhibition of GABAergic transmission enhances neurosteroid content in the rat brain. Neuropharmacology 35, 1299-1305 (1996).
52. Carboni E, Wieland S, Lan NC, Gee KW. Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Psychopharmacology 126, 173-178 (1996).
53. A receptors. Eur. J. Pharmacol. 325, 1-7 (1997).
54. Zimmerberg B, Rackow SH, George-Friedman KP. Sex-dependent behavioural effects of the neurosteroid allopregnanolone in neonatal and adult rats after postnatal stress. Pharmacol. Biochem. Behav. 64, 717-724 (1999).
55. Crawley J, Glowa JR, Majewska MD, Paul SM. Anxiolytic activity of an endogenous adrenal steroid. Brain Res. 398(2), 382-385 (1986).
56. Wieland S, Lan C, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 3αOH,5β-pregnan-3α-ol-one. Brain Res. 565, 263-268 (1991).
57. Reddy DS, Kulkarni SK. Differential anxiolytic effects of neurosteroids in the mirrored chamber behaviour test in mice. Brain Res. 752, 61-71 (1997).
58. Fernandez-Guasti A, Picazo O. Flumazenil blocks the anxiolytic action of allopregnanolone. Eur. J. Pharmacol. 281, 113-115 (1995).
59. Majewska MD, Schwartz RD. Pregnenolone-sulfate: an endogenous antagonist of the γ-aminobutyric acid receptor complex in brain? Brain Res. 404, 355-360 (1997).
60. Melchior CL, Ritzmann RF. Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze. Pharmacol. Biochem. Behav. 48, 893-897 (1994).
61. A receptor. Brain Res. 526, 143-146 (1990).
62. Baulieu E-E, Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive steroids. Proc. Natl. Acad. Sci. USA 95, 4089-4091 (1998).
63. Semeniuk T, Ghandri JS, LeMelledo J-M. Neuroactive steroids plasma levels in patients with generalized anxiety disorder. J. Neuropsychiatry Clin. 13, 396-398 (2001).
64. Heydari B, Le Melledo J-M. Decreased serum levels of pregnenolone sulfate in patients with generalized social phobia. (2004) (In Press).
65. Genazzani AR, Petragalia F, Bernardi F et al. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J. Clin. Endocrinol. Metab. 83, 2099-2103 (1998).
66. Wang M, Wahlström G, Bäckström T. The regional brain distribution of the neurosteroids pregnenolone and pregnenolone sulfate following intravenous infusion. J. Steroid Biochem. Mol. Biol. 62, 199-306 (1997).
67. Wu FS, Gibbs TT, Farbs DH. Pregnenolone sulfate: a positive allosteric modulator at the NMDA receptor. Mol. Pharmacol 40, 333-336 (1991).
68. Kash SF, Tecott LH, Hodge C, Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 96, 1698-703 (1999).
69. Shekhar A, Keim SR. LY-354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39, 1139-1146 (2000).
70. Sajdyk TJ, Shekhar A. Excitatory amino acid receptors antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acid A receptor blockade in the basolateral amygdala of rats. J. Pharmacol. Exp. Ther. 283, 969-77 (1997).
71. Spivak B, Maayan R,Kotler M et al. Elevated circulatory levels of GABA-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol. Med. 30, 1227-1231 (2000).
72. Strohle A, Romeo E, di Michele F et al. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry 159, 145-147 (2002).
73. Barbaccia ML, Roscetti G, Trabucchi M et al. Time-dependent changes in rat brain neuroactive steroid concentrations and GABA-A receptor function after acute stress. Neuroendocrinology 63, 166-172 (1996a).
74. Barbaccia M, Roscetti G, Bolacchi F et al. Stress-induced increase in brain neutoactive steroids: antagonism with abecamil. Pharmacol. Biochem. Behav. 54, 205-210 (1996).
75. Tait G, McManus K, Chrapko W, Lara N, Bellavance F, Le Mellédo J-M. Neuroactive steroid response to pentagastrin in patients with panic disorder and healthy volunteers. Psychoneuroendocrinology 27, 417-429 (2002).
76. Deci PA, Lydiard B, Santos AB, Arana GW. Oral contraceptive and panic disorder. J. Clin. Psychiatry 53, 163-165 (1992).
77. Ushiroyama T, Okamoto Y, Toyoda K, Sugimoto O. A case of panic disorder induced by oralcontraceptive. Acta Obstet. Gynecol Scand. 71, 78-80 (1992).
78. Price WA, Heil D. Estrogen-induced panic attacks. Psychosomatics 29, 433-435 (1988).
79. Korhonen S, Saarijarvi S, Aito M. Estradiol treatment of panic disorder in a fertile-aged woman. Human Psychopharmacol. 10, 485-486 (1995).
80. Concas A, Follesa P, Porcu P, Sogliano C, Biggio G. Oral contraceptives decrease cerebral concentrations of neurosteroids and modify GABAA receptors gene expression. Neuropychopharmacology 23, S24 (2000).
81. Van Megen HJGM. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmocology 114, 449-455 (1994).
82. McManus K, Tait GR, Bellavance F, Le Mellédo J-M. Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin. J. Affect. Disord. 66, 273-279 (2001).
83. Abdson JL, Liberzon I. Dose response of adrenocordcotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology 21, 485-494 (1999).
84. Purdy RH, Morrow AL, Moore PH Jr, Paul SM. Stress-induced elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl Acad. Sci. USA 88, 4553-4557 (1991).
85. Roy-Byrne PP, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am. J. Psychiatry 153, 1444-1449 (1996).
86. Finlay-Jones R, Brown GW. Type of stressful life events and the onset of anxiety and depressive disorders. Psychol. Med. 11, 803-815 (1981).
87. Faravelli D. Life events preceding the onset of panic disorder. J. Affect. Dis. 47, 458-460 (1985).
88. Roy-Byrne PP, Geraci M, Uhde T. Life events and the onset of panic disorder. Am. J. Psychiatry 143, 1424-1427 (1986).
89. McEwen BS, Seeman T. Protective and damaging effects of mediators of stress: elaborating and testing the concepts of allostasis and allostatic load. Ann. NY Acad. Sci. (1999).
90. Bremner JD, Randall P, Vermetten E et al. Magnetic resonance imaging-based measurement of hippocampal volume in post-traumatic stress disorder related to childhood physical and sexual abuse - a preliminary report. Biol. Psychiatry 41, 23-32 (1997).
91. De Bellis MD, Keshaven MS, Clark DB et al. Developmental traumatology Part II: brain development. Biol. Psychiatry 45, 1271-1284 (1999).
92. A receptors and modulated by endogenous steroids. Neuroscience 85, 557-567 (1998).
93. Patchev VK, Hassan AHS, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychapharmacology 15, 533-540 (1986).
94. Charney DS, Breier A, Jatlow PI, Heninger GR. Behavioural, biochemical and blood pressure responses to alprazolam in healthy subjects: interactions with Yohimbine. Psychopharmacology 88, 133-140 (1986).
95. Plotsky PM, Otto S, Sutton S. Neurotransmitter modulation of corticotropine-releasing factor secretion into the hypophysial portal circulation. Life Sci. 41, 1311-1317 (1987).
96. Calogero AE, Gallucci WT, Chrousos GP, Gold PW. Interaction between GABAergic neurotransmission and rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Res. 463, 28-36 (1988).
97. Torpy DJ, Grice GI, Hockings M, Walters MM, Crosbie GV, Jackson RV. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. J. Clin. Endocrinol. Metab. 79, 140-144 (1994).
98. Curtis GC, Abelson JL, Gold PW. Adrenocorticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol. Psychiatry 41, 76-85 (1997).
99. Tritos N, Kitraki E, Philippidis H, Stylianopolou F. Neurotransmitter modulation of glucocorticoid receptor mRNA levels in the rat hippocampus. Neuroendocrinology 69, 324-330 (1999).
100. Shelton KH, Nemeroff CB, Knoght DL, Owens MJ. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J. Neurosci. 20, 1240-1248 (2000).
101. Schmidt PJ, Purdy RH, Moore PH, Paul SM, Rubinow DR. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J. Clin. Endocrinol. Metab. 79, 1256-1260 (1994).
102. Wang M, Seippel L, Purdy RH, Backstrom T. Relationship between symptom severity and steroid variation inn women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5β-pregnan-20-one. J. Clin. Endocrinol. Metab. 81, 1076-1082 (1996).
103. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstetrics & Gynecology 90, 709-714 (1997).
104. Bicikova M, Dibbelt L, Hill M, Hampl R, Starka L. Allopregnanolone in women with premenstrual symptoms. Hormone Metab. Res. 30, 227-230 (1998).
105. Sundstrom I, Andersson A, Ashbrook D, Purdy RH, Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Clin. Neuroendocrinol. 67, 126-138 (1998).
106. Le Mellédo J-M, Van Driel M, Coupland NJ et al. Response to flumazenil in women with premenstrual dysphoric disorder. Am. J. Psychiatry 157, 821-823 (2000).
107. Romeo E, Strohle A, Spalletta G et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 155, 910-913 (1998).
108. Uzunova V, Sheline Y, Davis, JM et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Nat. Acad. Sci USA 95, 3239-3244 (1998).
109. Hoehn-Saric R, McLeod DR, Hipsley PA et al. Effect of fluvoxamine on panic disorder. J. Clin. Psychopharmqacology 13, 321-326 (1993).
110. Rocca P, Fonzo V, Scotta M et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr. Scand. 95, 444-450 (1997).
111. Van Ameringen M, Mancini C, Oakman J-M et al. Selective serotonin re-uptake inhibitors in the treatment of social phobia: the emerging gold standard. CNS Drugs 11, 307-315 (1999).
112. Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by ion mass fragmentography. Proc. Nat. Acad. Sci. USA 93, 12599-12604 (1996).
113. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Nat. Acad. Sci. USA 96, 13512-13517 (1999).
114. Monaghan EP, Navalta LA, Shum L, Asbrook UW, Lee DA. Initial human experience with ganaloxone, a neuroactive steroid with antiepileptic activity. Epilepsia 38, 1026-1031 (1997).